Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea.

ABL will receive $4.3 million up front and be eligible for $550 million in research, regulatory and sales milestones, plus royalties. ...